- The FDA has informed Rigel Pharmaceuticals Inc RIGL that data submitted in May from fostamatinib Phase 2 trial for COVID-19 is insufficient for an emergency use authorization (EUA).
- Rigel submitted clinical data from a 59-patient NIH/NHLBI-sponsored Phase 2 trial of fostamatinib for hospitalized COVID-19 patients.
- The Company is currently conducting a larger Phase 3 trial evaluating fostamatinib in hospitalized COVID-19 patients.
- The 308-patient trial is expected to be complete later in 2021.
- Rigel said that if the Phase 3 trial meets its endpoints, it plans to resubmit the EUA application with this additional data.
- Price Action: RIGL shares are down 18.40% at $3.37 during the premarket session on the last check Friday.
- Related content: Benzinga's Full FDA Calendar.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechNewsPenny StocksShort IdeasHealth CareSmall CapFDAMoversTrading IdeasGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
